Legal & General Group
ATXI

Legal & General Group’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Legal & General Group’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1
Closed -$5K – 3677
2021
Q1 		$5K Hold
1
– – ﹤0.01% 3482
2020
Q4 		$5K Hold
1
– – ﹤0.01% 3436
2020
Q3 		$9K Hold
1
– – ﹤0.01% 3277
2020
Q2 		$12K Buy
+1
New +$11.3K ﹤0.01% 3272

Other funds holding ATXI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Legal & General Group's ATXI Position: Q2 2021 in Review

Legal & General Group sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2021, closing a stake of 1 share — an estimated $5K sold.

Legal & General Group first reported a position in ATXI in Q2 2020 and held it in 4 quarters. The position peaked at $12K in Q2 2020. 24 funds tracked by Wall St. Rank hold ATXI as of Q2 2021.

  • Legal & General Group reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 1 Avenue Therapeutics, Inc. Common Stock share in Q2 2021, an estimated $5K.
  • Legal & General Group first reported a position in Avenue Therapeutics, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
  • Legal & General Group's Avenue Therapeutics, Inc. Common Stock position peaked at $12K in Q2 2020.
  • 24 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.